A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

Abstract Background Recent reports suggested combining ramucirumab with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) to overcome EGFR resistance in non–small cell lung cancer (NSCLC). Nonetheless, evidence supporting the activity of afatinib and ramucirumab is lacking. T...

Full description

Bibliographic Details
Main Authors: Chun-Yao Huang, Hui-Li Huang, Chou-Chin Lan, Yi-Chih Huang, Yao-Kuang Wu
Format: Article
Language:English
Published: BMC 2023-05-01
Series:BMC Cancer
Subjects:
Afatinib
Ramucirumab
Non–small cell lung cancer
EFGR mutation
Online Access:https://doi.org/10.1186/s12885-023-10909-z

Internet

https://doi.org/10.1186/s12885-023-10909-z

Similar Items